For Healthcare Professionals Outside the US
Tafinlar + Mekinist is indicated for adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection; for first-line treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation; for adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Home > Efficacy > Metastatic BRAF V600+ Melanoma > Overall Response rate
For first-line targeted therapy in patients with BRAF V600 positive metastatic melanoma

In 2 phase 3 studies, up to 69% of patients experienced complete or partial responses with first-line TAFINLAR + MEKINIST 1,2

Overall response rate of TAFINLAR® (dabrafenib) + MEKINIST® (trametinib)
  • Greater than 90% of patients achieved disease control with first-line TAFINLAR + MEKINIST1,2
  • The ORR in patients who received TAFINLAR + MEKINIST ranged from 67% to 69% compared with 53% in those who received TAFINLAR monotherapy or vemurafenib monotherapy1,2
  • TAFINLAR + MEKINIST has a low rate of primary resistancea (6%)1,2

a Primary resistance is defined as best response to therapy being progressive disease.

In a post hoc analysis across the 3 randomized studies, TAFINLAR + MEKINIST demonstrated high response rates even in patients with elevated LDH levels at baseline3

  • Data from the patients who received TAFINLAR + MEKINIST across the 3 randomized studies were pooled3
    • In patients with normal LDH levels at baseline, the ORR was 74%
    • In patients with LDH levels of >1 to ≤2 × ULN at baseline, the ORR was 59%
    • In patients with LDH levels of >2 × ULN at baseline, the ORR was 51%
CR, complete response; LDH, lactate dehydrogenase; ORR, overall response rate; PR, partial response; ULN, upper limit of normal.
References: 1. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib + trametinib in patients with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. Presented at: European Society for Medical Oncology; October 7-11, 2016; Copenhagen, Denmark. 2. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-451. 3. Long GV, Grob JJ, Nathan P, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomized trials. Lancet Oncol. 2016;17(12):1743-1754. 

COVID-19 Update

Novartis is closely monitoring the evolving COVID-19 pandemic. For the most recent information on how Novartis is responding, visit the COVID-19 Information Center.

During this time of uncertainty it is important to communicate with your patients about COVID-19 to clarify that they should not stop their treatments except under the direction of the treating physician, and to ensure that patients have sufficient drug to avoid any treatment interruptions.

Reach out to your Novartis representative with any questions related to Novartis products.

04/20  G-ONC-1230566

COMBI-AD was a double-blind, placebo-controlled, Phase 3 trial that compared Tafinlar + Mekinist vs placebo4


  • Resection of histologically confirmed Stage IIIA, B, or C with BRAF V600E or BRAF V600K mutation
  • ECOG performance status ≤1
  • No prior systemic anticancer treatment or radiotherapy for melanoma
2 mg QD (n=438)

Placebo (n=432)


  • Primary endpoint was RFS
  • Secondary endpoints were OS, distant metastasis-free survival, freedom from relapse, and safety
COMBI-d phase 3 study: Tafinlar® (dabrafenib) + Mekinist® (trametinib) vs Tafinlar® monotherapy